Intercept Pharmaceuticals Provides Business Update

8/2/18

NEW YORK, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended June 30, 2018.

“During the first half of 2018, we made good progress executing against our key strategic priorities in our Phase 3 NASH program and our PBC commercial efforts,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept. “Our leadership position in NASH is supported by what we believe to be the most comprehensive dataset of any ongoing development program and we remain on track to report top line data from the Phase 3 REGENERATE trial in first half of 2019. On the commercial front, the expansion of our U.S. sales and commercial infrastructure is expected to further enhance our capacity to provide access to Ocaliva to eligible PBC patients and the healthcare providers who treat them.”

Ocaliva® (obeticholic acid or OCA) Commercial Highlights

We recorded $43.2 million of Ocaliva net sales in the second quarter of 2018, as compared to $30.4 million in the prior year quarter. Ocaliva net sales in the second quarter of 2018 were comprised of U.S. net sales of $34.5 million and ex-U.S. net sales of $8.7 million, as compared to U.S. net sales of $27.9 million and ex-U.S. net sales of $2.6 million in the prior year quarter.

Ocaliva was approved in the United States by the U.S. Food and Drug Administration (“FDA”) in May 2016 for the treatment of primary biliary cholangitis (“PBC”) in combination with ursodeoxycholic acid (“UDCA”) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. We commenced sales and marketing of Ocaliva in the United States shortly after receiving marketing approval, and Ocaliva is now available to patients primarily through a network of specialty pharmacy distributors.

Ocaliva was granted conditional approval by the European Commission in December 2016 for the treatment of PBC in combination with UDCA in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA, and we commenced our European commercial launch in January 2017. Since January 2017, Ocaliva has also received regulatory approval in several of our target markets outside the United States and Europe, including Canada, Israel and Australia.

Selected Second Quarter 2018 Financial Results

Revenues

We recognized $43.6 million in total revenue in the quarter ended June 30, 2018, up from $30.9 million in total revenue in the quarter ended June 30, 2017. Total revenue in the second quarter of 2018 included $43.2 million of Ocaliva net sales and approximately $0.4 million of licensing revenue related to the amortization of upfront payments under our license agreement with Sumitomo Dainippon Pharma Co., Ltd., as compared to $30.4 million and approximately $0.4 million, respectively, in the prior year quarter.

Operating Expenses

Our cost of sales was $0.7 million in the second quarter of 2018, as compared to $0.3 million in the prior year quarter. Prior to the FDA’s approval of Ocaliva, we expensed costs related to the manufacturing and buildup of our Ocaliva commercial launch supplies. As a result, our cost of sales in the quarters ended June 30, 2018 and 2017 included only packaging and labeling expenses incurred during the quarter. We expect our cost of sales to remain negligible until the previously expensed supplies of Ocaliva are sold.

Our selling, general and administrative expenses decreased to $65.2 million in the quarter ended June 30, 2018, down from $66.9 million in the prior year quarter. The decrease was primarily driven by a decrease in consultant, legal and other spend.

Research and development expenses increased to $47.4 million in the quarter ended June 30, 2018, up from $44.2 million in the prior year quarter. The increase was primarily driven by an increase in OCA research and development activities.

In the quarters ended June 30, 2018 and 2017, we recorded $113.4 million and $111.4 million, respectively, in total operating expenses and $98.1 million and $96.0 million, respectively, in non-GAAP adjusted operating expenses, which excludes non-cash stock-based compensation expense of $14.1 million and $14.3 million, respectively, and depreciation expense of $1.1 million and $1.1 million, respectively. References in this press release to “non-GAAP adjusted operating expenses” mean our total operating expenses, as calculated and presented in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”), adjusted for the effects of two non-cash items: stock-based compensation and depreciation. See “Non-GAAP Financial Measures” below. A reconciliation of non-GAAP adjusted operating expenses to total operating expenses for all historical periods presented is included below under the heading “Reconciliation of Non-GAAP Adjusted Operating Expenses to Total Operating Expenses”.

Interest Expense

Our interest expense in the quarters ended June 30, 2018 and 2017 was $7.6 million and $7.3 million, respectively. Our interest expense is related to the $460.0 million aggregate principal amount of 3.25% Convertible Senior Notes due 2023 (the “Convertible Notes”) that we issued in July 2016.

Net Loss

During the second quarter of 2018, we reported a net loss of $75.2 million, down from a net loss of $86.6 million in the prior year quarter.

Cash Position

As of June 30, 2018, we had cash, cash equivalents and investment securities available for sale of approximately $538.3 million, including net proceeds of approximately $261.4 million from our registered public offering and concurrent private placement of common stock in April 2018. As of December 31, 2017, we had cash, cash equivalents and investment securities available for sale of approximately $414.9 million.

2018 Financial Guidance

Based on our second quarter results and our current outlook for the remainder of 2018, we are confirming our previously announced 2018 Ocaliva net sales guidance range of between $170 million and $185 million. In addition, we are confirming our previously announced 2018 non-GAAP adjusted operating expenses guidance range of between $390 million and $410 million. See “Non-GAAP Financial Measures” below. A quantitative reconciliation of projected non-GAAP adjusted operating expenses to total operating expenses is not available without unreasonable effort primarily due to our inability to predict with reasonable certainty the amount of future stock-based compensation expense.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.